How will AMYPAD help clinical trials?

The AMYPAD PNHS study heledp improve the understanding of disease pathophysiology. Also it gathered information about research participants, notably about the presence of biomarkers for Alzheimer’s disease, which can be used to select research participants for clinical trials. Also, it made the inclusion of research participants in clinical trials more efficient: participants from various Parent Cohorts had the advantage of having already been well-characterized by previous assessments. This prevents the undue inclusion in Alzheimer’s dementia prevention trials of people who are unlikely to develop Alzheimer’s dementia.